{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Synaptogyrines : Questions médicales les plus fréquentes",
"headline": "Synaptogyrines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Synaptogyrines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-06",
"dateModified": "2025-04-01",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Synaptogyrines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines de tissu nerveux",
"url": "https://questionsmedicales.fr/mesh/D009419",
"about": {
"@type": "MedicalCondition",
"name": "Protéines de tissu nerveux",
"code": {
"@type": "MedicalCode",
"code": "D009419",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.631"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Synaptogyrines",
"alternateName": "Synaptogyrins",
"code": {
"@type": "MedicalCode",
"code": "D062805",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Lingfei Li",
"url": "https://questionsmedicales.fr/author/Lingfei%20Li",
"affiliation": {
"@type": "Organization",
"name": "Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong SAR, China."
}
},
{
"@type": "Person",
"name": "Philip Wing-Lok Ho",
"url": "https://questionsmedicales.fr/author/Philip%20Wing-Lok%20Ho",
"affiliation": {
"@type": "Organization",
"name": "Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong SAR, China."
}
},
{
"@type": "Person",
"name": "Shirley Yin-Yu Pang",
"url": "https://questionsmedicales.fr/author/Shirley%20Yin-Yu%20Pang",
"affiliation": {
"@type": "Organization",
"name": "Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong SAR, China."
}
},
{
"@type": "Person",
"name": "Zoe Yuen-Kiu Choi",
"url": "https://questionsmedicales.fr/author/Zoe%20Yuen-Kiu%20Choi",
"affiliation": {
"@type": "Organization",
"name": "Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong SAR, China."
}
},
{
"@type": "Person",
"name": "Yasine Malki",
"url": "https://questionsmedicales.fr/author/Yasine%20Malki",
"affiliation": {
"@type": "Organization",
"name": "Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong SAR, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Associations of free sugars from solid and liquid sources with cardiovascular disease: a retrospective cohort analysis.",
"datePublished": "2023-04-24",
"url": "https://questionsmedicales.fr/article/37095459",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-023-15600-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Population-based assessment of cardiovascular complications of rheumatic heart disease in Fiji: a record-linkage analysis.",
"datePublished": "2023-04-24",
"url": "https://questionsmedicales.fr/article/37094887",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-070629"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cardiovascular Magnetic Resonance from Fetal to Adult Life-Indications and Challenges: A State-of-the-Art Review.",
"datePublished": "2023-04-23",
"url": "https://questionsmedicales.fr/article/37238311",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/children10050763"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fitness attenuates long-term cardiovascular outcomes in women with ischemic heart disease and metabolic syndrome.",
"datePublished": "2023-04-23",
"url": "https://questionsmedicales.fr/article/37181803",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ajpc.2023.100498"
}
},
{
"@type": "ScholarlyArticle",
"name": "The CombiConsultation for patients with diabetes, COPD and cardiovascular diseases: Evaluation of interventions and personal health-related goals.",
"datePublished": "2023-04-17",
"url": "https://questionsmedicales.fr/article/37095031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.sapharm.2023.04.118"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines de tissu nerveux",
"item": "https://questionsmedicales.fr/mesh/D009419"
},
{
"@type": "ListItem",
"position": 5,
"name": "Synaptogyrines",
"item": "https://questionsmedicales.fr/mesh/D062805"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Synaptogyrines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Synaptogyrines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Synaptogyrines",
"description": "Comment diagnostiquer une anomalie des synaptogyrines ?\nQuels examens sont utilisés pour évaluer les synaptogyrines ?\nLes tests génétiques sont-ils fiables pour les synaptogyrines ?\nQuels symptômes peuvent indiquer un problème avec les synaptogyrines ?\nPeut-on détecter les synaptogyrines par des analyses sanguines ?",
"url": "https://questionsmedicales.fr/mesh/D062805?mesh_terms=Cardiovascular+System&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Synaptogyrines",
"description": "Quels sont les symptômes associés aux dysfonctionnements des synaptogyrines ?\nLes troubles moteurs sont-ils liés aux synaptogyrines ?\nLes troubles cognitifs peuvent-ils être causés par des anomalies des synaptogyrines ?\nLes convulsions sont-elles fréquentes avec des problèmes de synaptogyrines ?\nPeut-on observer des changements de comportement liés aux synaptogyrines ?",
"url": "https://questionsmedicales.fr/mesh/D062805?mesh_terms=Cardiovascular+System&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Synaptogyrines",
"description": "Peut-on prévenir les troubles liés aux synaptogyrines ?\nLe dépistage précoce est-il important pour les synaptogyrines ?\nLes conseils génétiques sont-ils recommandés pour les familles ?\nY a-t-il des facteurs environnementaux à surveiller ?\nLes vaccinations peuvent-elles prévenir des troubles neurologiques ?",
"url": "https://questionsmedicales.fr/mesh/D062805?mesh_terms=Cardiovascular+System&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Synaptogyrines",
"description": "Quels traitements sont disponibles pour les troubles liés aux synaptogyrines ?\nLa thérapie génique est-elle une option pour les anomalies des synaptogyrines ?\nLes médicaments peuvent-ils améliorer les symptômes liés aux synaptogyrines ?\nDes interventions chirurgicales sont-elles possibles pour ces troubles ?\nLes thérapies physiques sont-elles bénéfiques pour les patients ?",
"url": "https://questionsmedicales.fr/mesh/D062805?mesh_terms=Cardiovascular+System&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Synaptogyrines",
"description": "Quelles complications peuvent survenir avec des troubles des synaptogyrines ?\nLes troubles de l'humeur sont-ils des complications possibles ?\nLes patients peuvent-ils développer des troubles psychiatriques ?\nLes complications peuvent-elles affecter la qualité de vie ?\nY a-t-il un risque accru de mortalité avec ces troubles ?",
"url": "https://questionsmedicales.fr/mesh/D062805?mesh_terms=Cardiovascular+System&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Synaptogyrines",
"description": "Quels sont les facteurs de risque pour les troubles des synaptogyrines ?\nL'hérédité joue-t-elle un rôle dans les troubles des synaptogyrines ?\nLes infections prénatales peuvent-elles affecter les synaptogyrines ?\nLe stress environnemental est-il un facteur de risque ?\nLes facteurs nutritionnels influencent-ils les troubles des synaptogyrines ?",
"url": "https://questionsmedicales.fr/mesh/D062805?mesh_terms=Cardiovascular+System&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des synaptogyrines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses de protéines neuronales."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer les synaptogyrines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie cérébrale et des biopsies peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils fiables pour les synaptogyrines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations spécifiques des synaptogyrines."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec les synaptogyrines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques, des convulsions ou des retards de développement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Peut-on détecter les synaptogyrines par des analyses sanguines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les synaptogyrines sont principalement étudiées dans le tissu cérébral."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes associés aux dysfonctionnements des synaptogyrines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles de l'humeur, des problèmes de mémoire et des convulsions."
}
},
{
"@type": "Question",
"name": "Les troubles moteurs sont-ils liés aux synaptogyrines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles moteurs peuvent survenir en raison de dysfonctionnements synaptiques."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs peuvent-ils être causés par des anomalies des synaptogyrines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent entraîner des troubles cognitifs et des retards de développement."
}
},
{
"@type": "Question",
"name": "Les convulsions sont-elles fréquentes avec des problèmes de synaptogyrines ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les convulsions sont un symptôme courant des dysfonctionnements des synaptogyrines."
}
},
{
"@type": "Question",
"name": "Peut-on observer des changements de comportement liés aux synaptogyrines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de comportement peuvent être observés en cas de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux synaptogyrines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de méthodes de prévention spécifiques pour ces troubles."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il important pour les synaptogyrines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un dépistage précoce peut aider à gérer les symptômes et améliorer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils recommandés pour les familles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider les familles à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à surveiller ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux peuvent influencer la santé neurologique, mais peu sont connus."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles prévenir des troubles neurologiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections qui affectent le système nerveux."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles liés aux synaptogyrines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments anticonvulsivants et des thérapies comportementales."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option pour les anomalies des synaptogyrines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore largement disponible pour ces troubles."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils améliorer les symptômes liés aux synaptogyrines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent aider à gérer les symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Des interventions chirurgicales sont-elles possibles pour ces troubles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les interventions chirurgicales sont rares et réservées aux cas graves de convulsions."
}
},
{
"@type": "Question",
"name": "Les thérapies physiques sont-elles bénéfiques pour les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les thérapies physiques peuvent aider à améliorer la motricité et la coordination."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles des synaptogyrines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles cognitifs sévères et des problèmes de développement."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur sont-ils des complications possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de l'humeur peuvent survenir en raison de dysfonctionnements synaptiques."
}
},
{
"@type": "Question",
"name": "Les patients peuvent-ils développer des troubles psychiatriques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles psychiatriques peuvent être associés à des anomalies des synaptogyrines."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent gravement affecter la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de mortalité avec ces troubles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains troubles graves liés aux synaptogyrines peuvent augmenter le risque de mortalité."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles des synaptogyrines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques et environnementaux peuvent augmenter le risque de troubles."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les troubles des synaptogyrines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles neurologiques peuvent être un facteur de risque."
}
},
{
"@type": "Question",
"name": "Les infections prénatales peuvent-elles affecter les synaptogyrines ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections prénatales peuvent influencer le développement neurologique."
}
},
{
"@type": "Question",
"name": "Le stress environnemental est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress environnemental peut contribuer à des troubles neurologiques chez certains individus."
}
},
{
"@type": "Question",
"name": "Les facteurs nutritionnels influencent-ils les troubles des synaptogyrines ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une nutrition inadéquate peut affecter le développement cérébral et synaptique."
}
}
]
}
]
}
The World Health Organization recommends a 10% total energy (TE%) limit for free sugars (i.e., added sugars and naturally occurring sugars in fruit juice, honey, and syrups) based on evidence linking ...
In this retrospective cohort study, we estimated free sugars from 24-h dietary recall (Canadian Community Health Survey, 2004-2005) in relationship to nonfatal and fatal CVD (Discharge Abstract and Ca...
Men 55 to 75 years of age had 34% higher CVD hazards with intakes of free sugars from solid sources ≥ 5 TE% vs. below (adjusted HR 1.34, 95% CI 1.05- 1.70). The other three age and sex-specific groups...
Our findings suggest that from a CVD prevention standpoint in men 55 to 75 years of age, there may be benefits from consuming less than 5 TE% as free sugars from solid sources....
To determine population-based rates of non-fatal complications of rheumatic heart disease (RHD)....
Retrospective cohort study based on multiple sources of routine clinical and administrative data amalgamated by probabilistic record-linkage....
Fiji, an upper-middle-income country, where most of the population has access to government-funded healthcare services....
National cohort of 2116 patients with clinically apparent RHD aged 5-69 years during 2008 and 2012....
The primary outcome was hospitalisation for any of heart failure, atrial fibrillation, ischaemic stroke and infective endocarditis. Secondary outcomes were first hospitalisation for each of the compli...
Among 2116 patients in the national cohort (median age, 23.3 years; 57.7% women), 546 (25.8%) were hospitalised for an RHD complication, a substantial proportion of all cardiovascular admissions in th...
Our study defines the burden of RHD-attributable morbidity in the general population of Fiji, potentially reflecting the situation in low-income and middle-income countries worldwide. Hospitalisation ...
Cardiovascular magnetic resonance (CMR) imaging offers a comprehensive, non-invasive, and radiation-free imaging modality, which provides a highly accurate and reproducible assessment of cardiac morph...
The prevalence of metabolic syndrome continues to increase steadily while fitness remains relatively low. The contribution of fitness on longer-term cardiovascular outcomes and mortality in individual...
Women's Ischemia Syndrome Evaluation (WISE) prospective cohort (enrolled 1996-2001) of women undergoing invasive coronary angiography with signs/symptoms of ischemic heart disease....
Investigated the association of fitness, defined as >7METs measured by self-reported Duke Activity Status Index (DASI), and both metabolic syndrome (ATPIII criteria) and dysmetabolism (ATPIII criteria...
Among the 492 women followed for a median of 8.6 years (range 0-11 years), 19.5% were fit-metabolically healthy (reference), 14.4% fit-metabolic syndrome, 29.9% unfit-metabolically healthy, and 36.2% ...
In a high risk cohort of women with signs/symptoms of ischemic heart disease, unfit-metabolically healthy and fit-metabolically unhealthy women were at higher risk of long-term MACE and mortality comp...
https://www.clinicaltrials.gov/ct2/show/NCT00000554 (NCT00000554)....
The CombiConsultation is a consultation with the community pharmacist for patients with diabetes, COPD and/or cardiovascular disease (CVD), aligned with the annual or quarterly consultation with the p...
To assess the number and types of personal health-related goals, drug-related problems (DRPs) and interventions identified by pharmacists during a CombiConsultation and to investigate which patients c...
Twenty-one Dutch community pharmacies and associated GP practices were included in the CombiConsultation study. CombiConsultations were performed, involving patients with diabetes, COPD and/or (at ris...
In 834 patients (49% men, mean age: 70 years), 939 DRPs were identified, mostly (potential) side effects (33%), undertreatment (18%) and overtreatment (14%). In 71% of the patients, one or more DRPs w...
The CombiConsultation can be used as a compact health service contributing to safe and effective use of medication for patients with diabetes, COPD and/or (at risk of) CVD, also in patients under 65 o...
Lipoprotein(a) is a recognized independent cardiovascular risk factor and apolipoprotein B (apoB) level better reflects the risk than LDL-cholesterol. Despite this cardiovascular prediction mostly rel...
422 presumably healthy subjects aged 19-84 were included. Lipid profile, Lp(a), apoB and small dense low-density lipoprotein cholesterol (sdLDL-C) were assayed. Subjects were divided at desirable cut-...
Women younger than 40 with low LDL-C may be at increased cardiovascular risk associated with elevated Lp(a) and apolipoprotein B levels. Inclusion of Lp(a) and apoB in the routine lipid testing provid...
Cardiovascular diseases have been the leading cause of death in the world for more than 20 years. They are generally unusual in premenopausal women due to the cardiovascular protection of endogenous e...
Establish a protocol for vascular risk screening in perimenopausal women from the community pharmacy....
Descriptive study from an opportunistic sample in a community pharmacy of women between 45 and 55 years old. Participants were cited at the pharmacy and their cholesterol and blood pressure levels, we...
18 forms were collected, with the average age of the applicants being 49 (SD 3) years old. 38.9% (CI95%: 17.3 a 64.3) had high blood pressure and 44.4% (CI95%: 21.5 a 69.2) had cholesterol levels equa...
The usefulness of vascular risk screening in perimenopausal women is confirmed. All this places value on the intervention of the community pharmacist in the detection and management of cardiovascular ...
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been shown to improve cardiovascular and renal outcomes in patients with established cardiovascular disease, chronic kidney disease (CKD), and ...
Growing evidence suggests that various reproductive factors, including early menarche, early menopause, and age at first birth, may increase the risk of developing cardiovascular disease (CVD) later i...
We obtained summary statistics for exposure from the largest genome-wide association studies of AFS and AFB. To serve as instrumental variables, we selected 259 SNPs associated with AFS and 81 SNPs as...
The genetic liability to later AFS was associated with decreased risks of heart failure (odd ratio [OR] 0.700; 95% confidence interval [CI] 0.639-0.767; p = 2.23 × 10...
Our results observed a causal relationship between later AFS, AFB and lower CVDs risk; it emphasizes the importance of providing sex education since early sex and birth may have undesirable effects. C...
Current cardiovascular disease prevention strategies are based on the management of cardiovascular risk as a continuum, redefining the therapeutic goals for each individual based on the estimated glob...